Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke).

Koga M, Toyoda K, Minematsu K, Yasaka M, Nagai Y, Aoki S, Nezu T, Hosomi N, Kagimura T, Origasa H, Kamiyama K, Suzuki R, Ohtsuki T, Maruyama H, Kitagawa K, Uchiyama S, Matsumoto M; J-STARS Investigators.

Stroke. 2018 Jan;49(1):107-113. doi: 10.1161/STROKEAHA.117.018387. Epub 2017 Nov 30.

2.

Factors Associated with Intima-Media Complex Thickness of the Common Carotid Artery in Japanese Noncardioembolic Stroke Patients with Hyperlipidemia: The J-STARS Echo Study.

Wada S, Koga M, Toyoda K, Minematsu K, Yasaka M, Nagai Y, Aoki S, Nezu T, Hosomi N, Kagimura T, Origasa H, Kamiyama K, Suzuki R, Ohtsuki T, Maruyama H, Kitagawa K, Uchiyama S, Matsumoto M; Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study Collaborators.

J Atheroscler Thromb. 2018 Apr 1;25(4):359-373. doi: 10.5551/jat.41533. Epub 2017 Nov 8.

3.

Time-related trends in variability of cIMT changes in statin trials.

Davidson MH, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM.

Data Brief. 2015 Dec 30;6:530-41. doi: 10.1016/j.dib.2015.12.029. eCollection 2016 Mar.

4.

Carotid Intima-media Thickness Measurements: Relations with Atherosclerosis, Risk of Cardiovascular Disease and Application in Randomized Controlled Trials.

Bots ML, Evans GW, Tegeler CH, Meijer R.

Chin Med J (Engl). 2016 Jan 20;129(2):215-26. doi: 10.4103/0366-6999.173500. Review.

5.

Association of carotid intraplaque hemorrhage and territorial acute infarction in patients with acute neurological symptoms using carotid magnetization-prepared rapid acquisition with gradient-echo.

Park JS, Kwak HS, Lee JM, Koh EJ, Chung GH, Hwang SB.

J Korean Neurosurg Soc. 2015 Feb;57(2):94-9. doi: 10.3340/jkns.2015.57.2.94. Epub 2015 Feb 26.

6.

Rationalizing prescribing for older patients with multimorbidity: considering time to benefit.

Holmes HM, Min LC, Yee M, Varadhan R, Basran J, Dale W, Boyd CM.

Drugs Aging. 2013 Sep;30(9):655-66. doi: 10.1007/s40266-013-0095-7. Review.

7.

Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients.

Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, Kazerooni EA, McCune WJ, Kaplan MJ.

PLoS One. 2012;7(5):e37000. doi: 10.1371/journal.pone.0037000. Epub 2012 May 14.

8.

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis.

Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, Manns B; Alberta Kidney Disease Network.

CMAJ. 2011 Nov 8;183(16):E1189-202. doi: 10.1503/cmaj.101280. Epub 2011 Oct 11. Review.

9.

Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness.

Migrino RQ, Bowers M, Harmann L, Prost R, LaDisa JF Jr.

J Cardiovasc Magn Reson. 2011 Aug 3;13:37. doi: 10.1186/1532-429X-13-37.

10.

The complex interplay between cholesterol and prostate malignancy.

Solomon KR, Freeman MR.

Urol Clin North Am. 2011 Aug;38(3):243-59. doi: 10.1016/j.ucl.2011.04.001. Epub 2011 Jun 22. Review.

11.

Statins for the primary prevention of cardiovascular disease.

Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. doi: 10.1002/14651858.CD004816.pub4. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD004816.

12.

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.

Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW.

BMJ. 2009 Jun 30;338:b2376. doi: 10.1136/bmj.b2376. Review.

13.

Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.

McTaggart F, Jones P.

Cardiovasc Drugs Ther. 2008 Aug;22(4):321-38. doi: 10.1007/s10557-008-6113-z. Epub 2008 Jun 14. Review.

14.

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial.

Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russell M, Silverman A, Stylianou M, Umans JG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F, Zhu J.

JAMA. 2008 Apr 9;299(14):1678-89. doi: 10.1001/jama.299.14.1678.

15.

Ultrasound settings significantly alter arterial lumen and wall thickness measurements.

Potter K, Reed CJ, Green DJ, Hankey GJ, Arnolda LF.

Cardiovasc Ultrasound. 2008 Jan 22;6:6. doi: 10.1186/1476-7120-6-6.

16.

Does pravastatin promote cancer in elderly patients? A meta-analysis.

Bonovas S, Sitaras NM.

CMAJ. 2007 Feb 27;176(5):649-54.

17.

Management of carotid artery stenosis. Update for family physicians.

Louridas G, Junaid A.

Can Fam Physician. 2005 Jul;51:984-9. Review.

18.

Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors.

Espeland MA, O'leary DH, Terry JG, Morgan T, Evans G, Mudra H.

Curr Control Trials Cardiovasc Med. 2005 Mar 10;6(1):3.

19.
20.

Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.

Warshafsky S, Packard D, Marks SJ, Sachdeva N, Terashita DM, Kaufman G, Sang K, Deluca AJ, Peterson SJ, Frishman WH.

J Gen Intern Med. 1999 Dec;14(12):763-74.

Supplemental Content

Support Center